Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Colorectal Neoplasms 17Neoplasm Metastasis 8Rectal Neoplasms 6Colonic Neoplasms 4Uveal Melanoma 3Stomach Neoplasms 2Neoplasms 2Recurrence 1Pancreatic Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Colorectal Cancer Metastatic 1Carcinoid Tumor 1Breast Neoplasms 1Biliary Tract Neoplasms 1Advanced Colorectal Cancer 1

Interventions

gallium Ga 68 dotatate 5Everolimus 5lanreotide 3cabozantinib 3Nivolumab 3pasireotide 2lutetium Lu 177 dotatate 2Temozolomide 2Sunitinib 2Octreotide 2Ga(III)-DOTATOC 2Erlotinib Hydrochloride 2Capecitabine 2zimberelimab 1veliparib 1telotristat ethyl 1recombinant interferon alpha 2b-like protein 1pertuzumab 1nintedanib 1ibrutinib 1ganitumab 1fluorodopa F 18 1carfilzomib 1aflibercept 1Sorafenib 1Somatostatin 1Serotonin 1Ramucirumab 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoid Tumor × aflibercept × Clear all
NCT01782443 2023-08-14

Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
19 enrolled 11 charts
Endocrine

Carcinoid Tumor, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡